GLP-1 Weight Loss in Plainview, NY -- What to Expect in the First 90 Days

Clinical overview

The first question most patients ask about GLP-1 weight loss at Stay Ageless Clinic in Plainview, NY is simple: when does it start working? The honest answer requires understanding what GLP-1 medications actually do -- and why the first 90 days look and feel different from any weight loss approach most patients have tried before.

Farina Sial, PA, MBA -- with 26 years at Mount Sinai South Nassau -- oversees all GLP-1 programs at Stay Ageless Clinic. Every patient starts with baseline bloodwork: fasting glucose, HbA1c, lipid panel, thyroid panel, comprehensive metabolic panel, and BMI assessment. This is not optional. It is the clinical foundation that allows safe prescribing and meaningful progress tracking at 90 days, 6 months, and 12 months.

How GLP-1 Medications Work

GLP-1 (Glucagon-Like Peptide-1) receptor agonists work through three simultaneous mechanisms that together produce significant and sustained weight loss:

Appetite suppression through central nervous system action -- GLP-1 receptors in the brain's hypothalamus regulate satiety. Semaglutide and tirzepatide activate these receptors, producing a profound reduction in hunger and food preoccupation that most patients describe as unlike anything they have experienced before. The food noise -- the constant background thinking about food -- largely disappears.

Gastric emptying delay -- GLP-1 medications slow the rate at which food moves from the stomach to the small intestine. This extends the feeling of fullness after meals and reduces the speed at which blood glucose rises after eating -- improving insulin sensitivity and reducing fat storage signals.

Insulin-glucagon balance correction -- GLP-1 agonists stimulate insulin release in response to meals while simultaneously suppressing glucagon. This normalization of the glucose-insulin cycle is why GLP-1 medications produce metabolic improvements -- reduced HbA1c, improved lipid profiles, lower blood pressure -- independently of weight loss.

Tirzepatide (Mounjaro/Zepbound) adds GIP (Glucose-Dependent Insulinotropic Polypeptide) receptor agonism to GLP-1 -- a dual mechanism that in clinical trials produced greater average weight loss than semaglutide alone.

Week By Week -- What to Expect in the First 90 Days

Weeks 1-4 -- Starting dose, appetite changes begin. Most patients notice reduced hunger within the first week. Nausea is the most common side effect at the starting dose -- typically mild and manageable. Weight loss of 2-5 lbs in the first month is typical. The starting dose is intentionally low to allow the body to adjust.

Weeks 5-8 -- First dose increase. Appetite suppression deepens. Nausea typically resolves or significantly improves. Weight loss accelerates. Energy levels may temporarily dip as caloric intake decreases -- protein intake is critical during this phase to preserve lean muscle mass.

Weeks 9-12 -- Approach to therapeutic dose. Most patients are approaching meaningful therapeutic dose levels by week 12. Average weight loss in clinical trials by week 12: 5-8% of body weight on semaglutide, 7-10% on tirzepatide. Metabolic markers begin improving -- blood pressure, fasting glucose, and lipids typically show measurable improvement by the first 90-day review.

What Stay Ageless Clinic Does Differently

GLP-1 prescribing without monitoring is not a medical program -- it is a prescription. At Stay Ageless Clinic, every GLP-1 patient receives baseline and quarterly bloodwork, individualized dose titration based on response and tolerance, nutrition guidance to protect lean muscle mass during weight loss, and access to aesthetic planning for GLP-1 face and body changes that occur with significant weight loss. Farina Sial, PA, MBA reviews every patient's results at 90 days and adjusts the protocol accordingly.

Learn more about the full medical weight loss program: stayageless.net/medical-weight-loss-plainview-ny.html